BiotechTube
Home/Renova Therapeutics/David Horwitz, MD, Ph.D., MBA
DH

David Horwitz, MD, Ph.D., MBA

Member, Scientific Advisory Board

Renova Therapeutics

Therapeutic Areas

CardiovascularMetabolic Disease

Renova Therapeutics Pipeline

DrugIndicationPhase
RT-100 (AC6)Symptomatic low ejection fraction heart failure (HFrEF)Phase 1/2
RT-200 (Ucn2)Type 2 Diabetes Mellitus (inadequately controlled)Phase 1/2